What question did this study set out to answer?

To evaluate the humoral and cellular immunogenicity and reactogenicity of mRNA and viral vector SARS-CoV-2 vaccines in adults living with HIV compared to HIV-negative controls.

March 31, 2022Open Access

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV: a nationwide prospective cohort study in the Netherlands

View Full Paper

Ask AI

Bookmark

Authors

KHKathryn S. Hensley MJMarlou J. Jongkees DGDaryl Geers

Discussion

Member takes

Overview

Prospective cohort study shows reduced antibody responses to SARS-CoV-2 mRNA vaccines in people living with HIV, suggesting booster doses may be needed to optimize immunity.

Key Points

To evaluate the humoral and cellular immunogenicity and reactogenicity of mRNA and viral vector SARS-CoV-2 vaccines in adults living with HIV compared to HIV-negative controls.
A nationwide prospective cohort study conducted in the Netherlands between February and September 2021 enrolled 1,154 adult PLWH (99% on antiretroviral therapy, median CD4+ T-cell count 710 cells/µL) and 440 HIV-negative controls without prior COVID-19.
Participants received BNT162b2, mRNA-1273, ChAdOx1-S, or Ad26.COV2.S, and were evaluated for anti-spike IgG antibody responses, T-cell activation by ELISpot and activation-induced marker assays, and reactogenicity.
Following mRNA vaccination, PLWH achieved a geometric mean concentration of 1,418 BAU/mL (95% CI, 1,322–1,523), with HIV status independently associated with a lower antibody response after adjusting for age, sex, and vaccine type (adjusted ratio 0.607, 95% CI, 0.508–0.725).
Among mRNA-vaccinated PLWH, higher antibody responses were predicted by CD4+ T-cell counts of 250–500 cells/µL (ratio 2.845, 95% CI, 1.876–4.314) or >500 cells/µL (ratio 2.936, 95% CI, 1.961–4.394), whereas viral load >50 copies/mL was associated with reduced responses (ratio 0.454, 95% CI, 0.286–0.720).
Antigen-specific IFN-γ, CD4+, and CD8+ T-cell responses in PLWH were comparable to HIV-negative controls, and reactogenicity was predominantly mild with no vaccine-related serious adverse events reported.

Cite This Study

Hensley et al. (2022) studied this question.

synapsesocial.com/papers/6aa2fbc50168768c14c07a90 https://doi.org/10.1101/2022.03.31.22273221

View Full Paper

Ask AI

Bookmark

March 31, 2022Open Access

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV: a nationwide prospective cohort study in the Netherlands

View Full Paper

Ask AI

Bookmark

Authors

KHKathryn S. Hensley MJMarlou J. Jongkees DGDaryl Geers

Discussion

Member takes

Overview

Prospective cohort study shows reduced antibody responses to SARS-CoV-2 mRNA vaccines in people living with HIV, suggesting booster doses may be needed to optimize immunity.

Key Points

To evaluate the humoral and cellular immunogenicity and reactogenicity of mRNA and viral vector SARS-CoV-2 vaccines in adults living with HIV compared to HIV-negative controls.
A nationwide prospective cohort study conducted in the Netherlands between February and September 2021 enrolled 1,154 adult PLWH (99% on antiretroviral therapy, median CD4+ T-cell count 710 cells/µL) and 440 HIV-negative controls without prior COVID-19.
Participants received BNT162b2, mRNA-1273, ChAdOx1-S, or Ad26.COV2.S, and were evaluated for anti-spike IgG antibody responses, T-cell activation by ELISpot and activation-induced marker assays, and reactogenicity.
Following mRNA vaccination, PLWH achieved a geometric mean concentration of 1,418 BAU/mL (95% CI, 1,322–1,523), with HIV status independently associated with a lower antibody response after adjusting for age, sex, and vaccine type (adjusted ratio 0.607, 95% CI, 0.508–0.725).
Among mRNA-vaccinated PLWH, higher antibody responses were predicted by CD4+ T-cell counts of 250–500 cells/µL (ratio 2.845, 95% CI, 1.876–4.314) or >500 cells/µL (ratio 2.936, 95% CI, 1.961–4.394), whereas viral load >50 copies/mL was associated with reduced responses (ratio 0.454, 95% CI, 0.286–0.720).
Antigen-specific IFN-γ, CD4+, and CD8+ T-cell responses in PLWH were comparable to HIV-negative controls, and reactogenicity was predominantly mild with no vaccine-related serious adverse events reported.

Cite This Study

Hensley et al. (2022) studied this question.

synapsesocial.com/papers/6aa2fbc50168768c14c07a90 https://doi.org/10.1101/2022.03.31.22273221

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark